Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Summary of Wireless Health and Fitness Devices Market report
The growth in various application areas and key regions, the growing R&D activity and the increasing...